Biomarkers in Urine Samples From Patients With Wilms Tumor
NCT ID: NCT01550393
Last Updated: 2016-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial studies biomarkers in urine from patients with Wilms tumor.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor
NCT01614808
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
NCT01542333
Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor
NCT01314391
Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors
NCT01004783
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
NCT01576198
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To validate the prognostic performance of specific-candidate Wilms tumor markers by measuring their urinary concentration using enzyme-linked immunosorbent assays (ELISAs) in urine specimens collected at diagnosis from 50 patients with favorable histology Wilms tumor who relapsed and 50 patients who did not relapse.
OUTLINE: Urine specimens are analyzed using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
proteomic profiling
enzyme-linked immunosorbent assay
laboratory biomarker analysis
medical chart review
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Urine specimens collected at diagnosis will be selected from patients with stage II-III Wilms tumors, with both local and non-local sites of disease relapse
* Clinical patient information (urinalysis/macro, age, gender, congenital defects/syndromes, comorbidities, tumor stage, size, pathology, therapy, outcome) available
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elizabeth A. Mullen, MD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AREN12B4
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000727337
Identifier Type: OTHER
Identifier Source: secondary_id
AREN12B4
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00702
Identifier Type: REGISTRY
Identifier Source: secondary_id
AREN12B4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.